Prevalence and antimicrobial resistance patterns of urinary tract infections at the university hospital center in Marrakech Morocco (2020-2024): a retrospective study.
- 1Faculty of Sciences-Semlalia, Laboratory of Water Sciences, Microbial Biotechnologies, and Natural Resources Sustainability (AQUABIOTECH), Unit of Microbial Biotechnologies, Agrosciences, and Environment (BIOMAGE) CNRST Labeled Research Unit N°4, Cadi Ayyad University, PO Box 2390, Marrakech, 40000, Morocco. [email protected].
- 2Faculty of Sciences-Semlalia, Laboratory of Water Sciences, Microbial Biotechnologies, and Natural Resources Sustainability (AQUABIOTECH), Unit of Microbial Biotechnologies, Agrosciences, and Environment (BIOMAGE) CNRST Labeled Research Unit N°4, Cadi Ayyad University, PO Box 2390, Marrakech, 40000, Morocco. [email protected].
- 3Department of Microbiology, Mohamed VI University Hospital Center, Marrakech, Morocco.
Abstract
Objective
To determine the prevalence, epidemiological and microbiological characteristics of urinary tract infections (UTIs), and to assess antimicrobial resistance (AMR) trends at the University Hospital Center Mohammed VI, Marrakech, over a five-year period.Methods
A retrospective cross-sectional study was conducted from January 2020 to December 2024. All urine specimens processed at the microbiology laboratory were reviewed. Duplicate isolates were excluded, and only the first positive isolate per patient per infectious episode was retained. Bacterial identification was performed using MALDI-TOF MS, and antimicrobial susceptibility testing was carried out using disk diffusion and the BD Phoenix® automated system. For consistency, AST results were rechecked and interpreted according to a single harmonized CA-SFM/EUCAST 2025 guideline version. Temporal trends in resistance were assessed using beta-regression models, with annual changes expressed as percentage-point variation per year and p-values adjusted using the Benjamini-Hochberg false discovery rate procedure.Results
Of 62,788 urine specimens, 8,231 were culture-positive 13.1%. Prevalence rose from 11.5% in 2020 to 14.9% in 2022, then stabilized at 12-13% in 2023-2024. Women accounted for 59.6% of cases, and patients ≥ 60 years were the most affected. Escherichia coli was the leading uropathogens 47.9%, followed by Klebsiella pneumoniae 16.7% and Enterococcus spp. 4.6%. Significant increases in resistance were observed for several clinically important antimicrobials. Amoxicillin-clavulanate resistance increased significantly in both E. coli (+ 6.00% points/year; 95% CI: 2.83-8.82; FDR-p < 0.001) and K. pneumoniae (+ 5.21% points/year; 95% CI: 2.08-8.03; FDR-p = 0.002). Ceftriaxone and piperacillin-tazobactam resistance increased significantly in E. coli, while carbapenem resistance increased significantly in both species. Fluoroquinolone resistance also showed significant upward trends in E. coli and K. pneumoniae. Among aminoglycosides, amikacin resistance increased significantly in both species, whereas gentamicin resistance increased significantly only in E. coli. No significant temporal trend was observed for trimethoprim-sulfamethoxazole resistance in either species.Conclusion
UTIs remain common, with E. coli and K. pneumoniae showing increasing resistance trends, particularly against β-lactams, fluoroquinolones, carbapenems and aminoglycosides. These findings underscore the importance of ongoing surveillance and support the implementation of antimicrobial stewardship strategies.
Related
- Bloodstream Infections in Patients with Malignancy: Microbiological Epidemiology, Antimicrobial Resistance, and Factors Associated with Mortality in a Nine-Year Single-Center Retrospective Cohort
- Genomic analysis and antimicrobial resistance profiling of Klebsiella pneumoniae clinical isolates from urinary tract infections in India: prevalence of class A β-lactamase with molecular docking and simulation insights.
- Epidemiology, Clinical Profiles, Antimicrobial Resistance, and Inflammatory Risk Factors of Aeromonas Infections in Hospitalized Patients: A Retrospective Cohort Study from a Hospital in Zhoushan Archipelago, China
- Prevalence of antimicrobial resistance in Campylobacter spp. and Salmonella spp. in Switzerland 2007–2022: a retrospective observational study
- Azithromycin in crisis: antimicrobial resistance, diagnostics gaps, and vaccine-linked stewardship for enteric infections in low- and middle-income countries
BibTeX
@article{ellehah2026prevalence,
title = {{Prevalence and antimicrobial resistance patterns of urinary tract infections at the university hospital center in Marrakech Morocco (2020-2024): a retrospective study.}},
author = {Zakaria Ellehah and Lahcen Ouahmane and Asmae Lamrani Hanchi and Nabila Soraa},
journal = {BMC microbiology},
year = {2026},
month = jul,
doi = {10.1186/s12866-026-05425-6},
url = {https://europepmc.org/article/MED/42897447},
note = {CC BY},
}
RIS
TY - JOUR
TI - Prevalence and antimicrobial resistance patterns of urinary tract infections at the university hospital center in Marrakech Morocco (2020-2024): a retrospective study.
AU - Zakaria Ellehah
AU - Lahcen Ouahmane
AU - Asmae Lamrani Hanchi
AU - Nabila Soraa
PY - 2026
DA - 2026/07/01
JO - BMC microbiology
DO - 10.1186/s12866-026-05425-6
UR - https://europepmc.org/article/MED/42897447
AB - Objective To determine the prevalence, epidemiological and microbiological characteristics of urinary tract infections (UTIs), and to assess antimicrobial resistance (AMR) trends at the University Hospital Center Mohammed VI, Marrakech, over a five-year period.Methods A retrospective cross-sectional study was conducted from January 2020 to December 2024. All urine specimens processed at the microbiology laboratory were reviewed. Duplicate isolates were excluded, and only the first positive isolate per patient per infectious episode was retained. Bacterial identification was performed using MALDI-TOF MS, and antimicrobial susceptibility testing was carried out using disk diffusion and the BD Phoenix® automated system. For consistency, AST results were rechecked and interpreted according to a single harmonized CA-SFM/EUCAST 2025 guideline version. Temporal trends in resistance were assessed using beta-regression models, with annual changes expressed as percentage-point variation per year and p-values adjusted using the Benjamini-Hochberg false discovery rate procedure.Results Of 62,788 urine specimens, 8,231 were culture-positive 13.1%. Prevalence rose from 11.5% in 2020 to 14.9% in 2022, then stabilized at 12-13% in 2023-2024. Women accounted for 59.6% of cases, and patients ≥ 60 years were the most affected. Escherichia coli was the leading uropathogens 47.9%, followed by Klebsiella pneumoniae 16.7% and Enterococcus spp. 4.6%. Significant increases in resistance were observed for several clinically important antimicrobials. Amoxicillin-clavulanate resistance increased significantly in both E. coli (+ 6.00% points/year; 95% CI: 2.83-8.82; FDR-p < 0.001) and K. pneumoniae (+ 5.21% points/year; 95% CI: 2.08-8.03; FDR-p = 0.002). Ceftriaxone and piperacillin-tazobactam resistance increased significantly in E. coli, while carbapenem resistance increased significantly in both species. Fluoroquinolone resistance also showed significant upward trends in E. coli and K. pneumoniae. Among aminoglycosides, amikacin resistance increased significantly in both species, whereas gentamicin resistance increased significantly only in E. coli. No significant temporal trend was observed for trimethoprim-sulfamethoxazole resistance in either species.Conclusion UTIs remain common, with E. coli and K. pneumoniae showing increasing resistance trends, particularly against β-lactams, fluoroquinolones, carbapenems and aminoglycosides. These findings underscore the importance of ongoing surveillance and support the implementation of antimicrobial stewardship strategies.
SN - 1471-2180
ER -